Lawrenz Joshua M, Johnson Samuel R, Zhu Kevin, McKeon Mallory, Moran Cullen P, Vega Jose, Hajdu Katherine S, Norris James P, Luo Leo Y, Shinohara Eric T, Cates Justin M M, Rubin Brian P, Reith John D, Halpern Jennifer L, Mesko Nathan W, Schwartz Herbert S, Nystrom Lukas M, Holt Ginger E
Department of Orthopaedic Surgery, Vanderbilt University Medical Center, Nashville 37232, TN, USA.
Department of Orthopaedic Surgery, Cleveland Clinic, Cleveland 44195, OH, USA.
Sarcoma. 2022 Aug 22;2022:2091677. doi: 10.1155/2022/2091677. eCollection 2022.
Radiation after resection of an atypical lipomatous tumor (ALT) is controversial. This study evaluates local control and complications after the first resection of ALTs of the extremity with or without adjuvant radiation.
A dual institution, retrospective review of patients treated from 1995 to 2020 with first-time resection of an ALT in the extremity was performed. In total, 102 patients underwent adjuvant radiation (XRT group) and 68 patients were treated with surgery alone (no-XRT group). The median follow-up time was 4.6 years (interquartile range (IQR) 2.0-7.3 years). The median radiation dose was 60 Gy (IQR 55-66 Gy). Univariable and multivariable analyses evaluated the association of patient, tumor, and treatment variables with recurrence and complications. Kaplan-Meier analysis evaluated local recurrence-free survival (LRFS) and time to complication.
The overall incidence of local recurrence was 1% (1/102) in the XRT group and 24% (16/68) in the no-XRT group ( < 0.001). The median time-to-recurrence was 8.2 years (IQR 6.5-10.5 years). In the XRT and the no-XRT groups, 5-yr LRFS was 98% and 92% (=0.21) and 10-yr LRFS was 98% and 41% ( < 0.001), respectively. The absence of radiation (HR = 23.63, 95% CI (3.09-180.48); < 0.001) and R2 surgical resection margins (HR = 11.04, 95% CI (2.07-59.03); < 0.001) incurred a 23-fold and 11-fold increased risk of local recurrence, respectively, while tumor size, depth, location, and neurovascular involvement were not found to be independent predictors of recurrence. The complication rate was 37% (38/102) in the XRT group and 10% (7/68) in the no-XRT group ( < 0.001). Eight patients (8/102, 8%) required surgical management for complication in the XRT group compared with two patients (2/68, 3%) in the no-XRT group (=0.10). Higher radiation dose had a modest correlation with increased severity of complication (=0.24; =0.02).
Adjuvant radiation after first-time resection of an ALT of the extremity was associated with a significantly reduced risk of local recurrence but a three-fold increase in complication rate. These data support a 10-year follow-up for these patients and inform a notable clinical trade-off if considering adjuvant radiation for this tumor with recurrent potential.
非典型脂肪瘤性肿瘤(ALT)切除术后的放疗存在争议。本研究评估了肢体ALT首次切除后辅助放疗与不放疗情况下的局部控制情况及并发症。
对1995年至2020年期间接受肢体ALT首次切除治疗的患者进行双机构回顾性研究。共有102例患者接受辅助放疗(XRT组),68例患者仅接受手术治疗(非XRT组)。中位随访时间为4.6年(四分位间距(IQR)2.0 - 7.3年)。中位放疗剂量为60 Gy(IQR 55 - 66 Gy)。单因素和多因素分析评估了患者、肿瘤和治疗变量与复发及并发症的相关性。Kaplan-Meier分析评估局部无复发生存率(LRFS)和并发症发生时间。
XRT组局部复发的总体发生率为1%(1/102),非XRT组为24%(16/68)(P < 0.001)。复发的中位时间为8.2年(IQR 6.5 - 10.5年)。在XRT组和非XRT组中,5年LRFS分别为98%和92%(P = 0.21),10年LRFS分别为98%和41%(P < 0.001)。未进行放疗(HR = 23.63,95%可信区间(CI)(3.09 - 180.48);P < 0.001)和R2手术切缘(HR = 11.04,95% CI(2.07 - 59.03);P < 0.001)分别使局部复发风险增加23倍和11倍,而肿瘤大小、深度、位置和神经血管受累情况未被发现是复发的独立预测因素。XRT组的并发症发生率为37%(38/102),非XRT组为10%(7/68)(P < 0.001)。XRT组有8例患者(8/102,8%)因并发症需要手术处理,而非XRT组有2例患者(2/68,3%)(P = 0.10)。较高的放疗剂量与并发症严重程度增加有适度相关性(P = 0.24;P = 0.02)。
肢体ALT首次切除后辅助放疗与局部复发风险显著降低相关,但并发症发生率增加了两倍。这些数据支持对这些患者进行10年随访,并为考虑对这种有复发可能的肿瘤进行辅助放疗时显著的临床权衡提供了依据。